DDInter1628 DDInter1270
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Haematuria
Haematuria {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is bound by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Ruxolitinib {u} (Compound) downregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is upregulated by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ruxolitinib (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ruxolitinib (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ruxolitinib (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Naxitamab
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Naxitamab
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Naxitamab
Ruxolitinib (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is bound by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ruxolitinib (Compound) downregulates HDAC6 (Gene) and HDAC6 (Gene) is upregulated by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab